CINCINNATI, Aug. 20 /PRNewswire-FirstCall/ -- Kendle a leading, global full-service clinical research organization, today announced it will webcast its Investor Day on Wednesday, Aug. 22, 2007 from 1 to 4 p.m. Eastern Time. A conference call also is being made available. All interested parties are invited to listen as Chairman and Chief Executive Officer Candace Kendle, PharmD, and members of the Kendle management team share the company’s perspective on the latest industry trends and growth plans for the future, followed by a question and answer session with live participants.
(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )
Webcast Instructions
To access the Kendle Investor Day webcast and slide presentation, go to http://www.kendle.com or http://www.videonewswire.com/event.asp?id=41930 prior to the event’s start at 1 p.m. Eastern Time. Instructions are provided at both sites. An archived version of the presentation will be available on http://www.kendle.com (click on “Investors”) for on-demand replay beginning Aug. 23, 2007 through 5 p.m. Eastern Time on Nov. 22, 2007. Please note webcast participants will not be able to ask questions.
System requirements for the Webcast include The Windows Media Player software, downloadable at no charge from http://www.microsoft.com/windows/windowsmedia/default.aspx and at least a 56Kbps connection to the Internet. Anyone experiencing problems listening to the webcast should send an e-mail to: webcast@multivu.com.
Conference Call Instructions
To listen to the Kendle Investor Day presentation via conference call, interested parties in the United States and Canada should dial (800) 399-0069. Participants outside North America should dial (706) 643-3694. A replay will be available beginning Aug. 23, 2007, through Sept. 21 by dialing (706) 645- 9291 and entering conference ID number 13949393. Please note conference call participants will not be able to ask questions.
About Kendle
Kendle International Inc. is among the world’s leading global clinical research organizations and is the fourth-largest provider of Phase II-IV clinical development services worldwide. We deliver innovative and robust clinical development solutions -- from first-in-human studies through market launch and surveillance -- to help the world’s biopharmaceutical companies maximize product life cycles and grow market share.
Our global clinical development business is focused on five regions -- North America, Europe, Asia/Pacific, Latin America and Africa -- to meet customer needs. With the expertise of our more than 3,000 associates worldwide, Kendle has conducted clinical trials and provided regulatory and pharmacovigilance services in more than 80 countries. The company was named the “Top CRO to Work With” in the Thomson CenterWatch 2007 Survey of U.S. Investigative Sites.
Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the Company’s Web site at http://www.kendle.com.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comKendle International Inc.
CONTACT: Patty Frank, Investors, +1-513-763-1992, or Lori Dorer, Media,+1-513-345-1685, both of Kendle International Inc.
